Bexarotene, a retinoid X receptor (RXR) agonist, is approved by FDA to treat cutaneous T-
cell lymphoma. However, it has also demonstrated promising therapeutic potential for …

Amyloid beta (Aβ) oligomers are the most neurotoxic aggregates causing neuronal death
and cognitive damage. A detailed elucidation of the aggregation pathways from oligomers to …

After 15 years of research into Alzheimer's disease (AD) therapeutics, including billions of
US dollars provided by federal agencies, pharmaceutical companies, and private …

Alzheimer's disease (AD) is characterized by fibrillar deposits of amyloid-β (Aβ) peptides
and neurofibrillary tangles of Tau proteins. Aβ peptides are composed of 37–49 residues …

Despite the constant progress in the understanding of the etiopathogenesis of Alzheimer's
disease (AD) over the last 50 years, just four long-standing drugs are currently used for AD …

Heavy evidence has confirmed that Aβ42 oligomers are the most neurotoxic aggregates and
play a critical role in the occurrence and development of Alzheimer's disease by causing …

As the world population ages, there will be an increasing need for effective therapies for
aging‐associated neurodegenerative disorders, which remain untreatable. Dementia due to …

A better understanding of the abnormal protein aggregation and the effect of anti-
aggregation agents on the fibrillation pathways and the secondary structure of aggregates …

As one of the main pathmechanisms of Alzheimer's disease (AD), amyloid-β (Aβ) is widely
considered to be the prime target for the development of AD therapy. Recently …

The extraneuronally deposited senile plaques, composed of neurotoxic aggregates of Aβ
fibril, define Alzheimer's disease (AD). Natural compounds have been tested for their …